The closing price of Globus Medical Inc (NYSE: GMED) was $51.98 for the day, up 0.64% from the previous closing price of $51.65. In other words, the price has increased by $+0.33 from its previous closing price. On the day, 970390 shares were traded.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Ratios:
Our analysis of GMED’s different ratios will help us gain a deeper understanding of the company. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 13.59 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 42.59. For the most recent quarter (mrq), Quick Ratio is recorded 2.72 and its Current Ratio is at 4.88. In the meantime, Its Debt-to-Equity ratio is 0.13 whereas as Long-Term Debt/Eq ratio is at 0.13.
On October 20, 2023, ROTH MKM started tracking the stock assigning a Buy rating and target price of $75.
Stifel Upgraded its Hold to Buy on September 19, 2023, while the target price for the stock was maintained at $61.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Mar 15 ’24 when Norwalk Leslie V sold 10,590 shares for $51.99 per share. The transaction valued at 550,574 led to the insider holds 17,419 shares of the business.
Huller Kelly sold 7,500 shares of GMED for $405,730 on Mar 01 ’24. The SVP, GC, Corporate Secretary now owns 0 shares after completing the transaction at $54.10 per share. On May 15 ’23, another insider, Lemaitre Dan, who serves as the Director of the company, sold 43,450 shares for $56.98 each. As a result, the insider received 2,475,977 and left with 10,800 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, GMED now has a Market Capitalization of 6.99B and an Enterprise Value of 6.99B. As of this moment, Globus’s Price-to-Earnings (P/E) ratio for their current fiscal year is 44.63, and their Forward P/E ratio for the next fiscal year is 15.73. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 2.76. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.49 while its Price-to-Book (P/B) ratio in mrq is 1.77. Its current Enterprise Value per Revenue stands at 4.46 whereas that against EBITDA is 20.18.
Stock Price History:
Over the past 52 weeks, GMED has reached a high of $62.88, while it has fallen to a 52-week low of $43.38. The 50-Day Moving Average of the stock is 54.06, while the 200-Day Moving Average is calculated to be 53.27.
Shares Statistics:
GMED traded an average of 1.19M shares per day over the past three months and 1.28M shares per day over the past ten days. A total of 113.91M shares are outstanding, with a floating share count of 112.00M. Insiders hold about 17.26% of the company’s shares, while institutions hold 80.19% stake in the company. Shares short for GMED as of Feb 29, 2024 were 5.73M with a Short Ratio of 4.80, compared to 5.32M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 4.24% and a Short% of Float of 5.12%.
Earnings Estimates
The firm’s stock currently is rated by 15 analysts. On average, analysts expect EPS of $0.57 for the current quarter, with a high estimate of $0.62 and a low estimate of $0.49, while EPS last year was $0.53. The consensus estimate for the next quarter is $0.66, with high estimates of $0.69 and low estimates of $0.63.
Analysts are recommending an EPS of between $2.72 and $2.68 for the fiscal current year, implying an average EPS of $2.69. EPS for the following year is $3.29, with 15 analysts recommending between $3.9 and $3.06.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 14 analysts. It ranges from a high estimate of $598.49M to a low estimate of $566.4M. As of the current estimate, Globus Medical Inc’s year-ago sales were $276.69M, an estimated increase of 111.90% from the year-ago figure. For the next quarter, 14 analysts are estimating revenue of $616.39M, an increase of 111.40% less than the figure of $111.90% in the same quarter last year. There is a high estimate of $623M for the next quarter, whereas the lowest estimate is $606.4M.
A total of 15 analysts have provided revenue estimates for GMED’s current fiscal year. The highest revenue estimate was $2.48B, while the lowest revenue estimate was $2.44B, resulting in an average revenue estimate of $2.46B. In the same quarter a year ago, actual revenue was $1.57B, up 57.10% from the average estimate. Based on 15 analysts’ estimates, the company’s revenue will be $2.65B in the next fiscal year. The high estimate is $2.71B and the low estimate is $2.61B. The average revenue growth estimate for next year is up 7.60% from the average revenue estimate for this year.
